Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Faculty Farshid Dayyani, MD, PhD
Professor of Clinical Medicine
Medical Director, Stern Center for Cancer Clinical Trials and Research
Associate Director for Translational Science
UCI Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, California
Caroline Kuhlman, MSN, APRN-BC
Nurse Practitioner
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts
Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Henry Ford Cancer Institute
Wayne State University
Detroit, Michigan
Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio
Meeting space has been assigned to provide a satellite symposium supported by Ipsen Biopharmaceuticals Inc during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD)
Risk factors for the development of pancreatic cancer, such as family history, genetic predisposition syndromes, smoking, obesity, diet and metabolic diseases
Rationale for the high proportion of PAD cases diagnosed in the advanced stages of the disease
Factors contributing to the aggressive nature of PAD; prognosis associated with advanced disease
Common presenting symptoms of PAD, such as asthenia, anorexia, weight loss, pain and jaundice
Recent Advances in Up-Front Treatment for Metastatic PAD
Impact of age, performance status, comorbidities, patient preferences and prior (neo)adjuvant therapy, if any, on the choice of first-line treatment for metastatic PAD
Historical data establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
Proposed mechanism of improved delivery of cytotoxic therapy to pancreatic cancer cells with nanoliposomal irinotecan (nal-IRI) compared to that with conventional chemotherapy
Key efficacy and safety outcomes reported with nal-IRI, fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for previously untreated metastatic PAD
FDA approval of up-front NALIRIFOX for patients with metastatic PAD; optimal selection of candidates for this regimen
Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Metastatic PAD
Key factors influencing the selection and sequencing of available therapies for R/R metastatic PAD
Long-term efficacy and safety findings with nal-IRI in combination with 5-FU/LV after disease progression on gemcitabine-based therapy
Patient selection for and practical integration of nal-IRI into treatment in the R/R setting
Other evidence-based chemotherapeutic agents or regimens for patients with progressive metastatic PAD
Tolerability and Other Practical Considerations with Nal-IRI
Comparative tolerability/toxicity profile of NALIRIFOX versus other commonly employed first-line regimens, such as FOLFIRINOX and gemcitabine/nab paclitaxel
Rates of diarrhea and other gastrointestinal issues documented with nal-IRI; indications for prophylactic antidiarrheals and/or antiemetics for patients who are about to start treatment
Incidence and severity of cytopenias with nal-IRI; role of growth factor use and appropriate monitoring of complete blood counts during therapy
Recommended dosing of nal-IRI as part of the first-line NALIRIFOX regimen versus in the R/R setting
Role of PARP Inhibitor Maintenance in the Treatment of Newly Diagnosed Metastatic PAD
Incidence of BRCA1/2 mutations and other related genetic abnormalities in patients with PAD
Optimal approach to genetic testing for patients with PAD
Mechanism of antitumor activity of PARP inhibitors and rationale for their use as maintenance therapy for patients with metastatic PAD and a documented BRCA mutation
Long-term findings with and optimal integration of olaparib into maintenance therapy after first-line chemotherapy for patients with metastatic PAD and a germline BRCA mutation
Spectrum, frequency and optimal prevention and management of toxicities documented with olaparib
Potential Utility of Tumor Treating Fields (TTFields) for the Management of PAD
Mechanism of action of TTFields and biological rationale for their investigation in locally advanced PAD
Emerging positive findings with TTFields in combination with gemcitabine and nab paclitaxel as front-line treatment for locally advanced PAD
Management algorithms for TTFields-associated skin toxicities and other practical considerations related to this treatment approach
Importance of Palliative Care for Advanced PAD
Appropriate assessment of symptom burden, psychological status and social support for patients with PAD
Potential impact of early palliative care on clinical, quality-of-life and survival outcomes
Optimal mitigation and management of specific symptoms related to PAD, such as pain, jaundice, delayed gastric emptying, venous thromboembolism, anorexia, cachexia and weight loss
Rates of depression and anxiety among patients with advanced PAD; available support systems
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
Recognize FDA-approved and commonly employed treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these agents and regimens.
Appraise available Phase III data with PARP inhibitor maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings.
Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.
Recall the biological rationale for and available and emerging data with investigational approaches currently in clinical testing for PAD, and appropriately refer patients for trial participation.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/PancreaticCancer/ILNA
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Kuhlman and Ms Wagner have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Dayyani — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Jazz Pharmaceuticals Inc, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Natera Inc, Pfizer Inc, Taiho Oncology Inc; Speakers Bureaus: Astellas, Ipsen Biopharmaceuticals Inc, Sirtex Medical Ltd, Takeda Pharmaceuticals USA Inc.
Dr Philip — Advisory Committees: Agenus Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Gilead Sciences Inc, HUYA Bioscience International, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Pfizer Inc, Processa Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen, BioNTech SE, Moderna, Novocure Inc; Data and Safety Monitoring Boards/Committees: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureaus: Astellas, Incyte Corporation.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by an educational grant from Ipsen Biopharmaceuticals Inc.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
